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Chronic Toxoplasmosis and CD8 Exhaustion
Toxoplasmosis caused by Toxoplasma gondii (T. gondii), an
obligate intercellular protozoan, is considered to be a leading
cause of foodborne mortality in the United States (www.cdc.gov).
Even in the post-HAART era, fatal toxoplasmic encephalitis (TE)
due to reactivation of chronic Toxoplasma infection remains a
major problem in Toxoplasma-seropositive AIDS patients in
developing countries [1]. In warm-blooded intermediate hosts
(including humans), the parasite undergoes stage conversion
between the rapidly proliferating tachyzoite, which is considered
to be responsible for acute toxoplasmosis, and the relatively
quiescent, slowly replicating, encysted bradyzoite that can persist
for life. However, in the immunocompromised such as AIDS
patients, the parasite converts from a bradyzoite to a tachyzoite
stage, leading to TE [2]. Similarly, repeated reactivations can also
occur in congenitally infected individuals [3]. Tachyzoite–
bradyzoite interconversion is believed to play a central role not
only in establishing the chronic infection but also in disease
recrudescence [2]. However, factors responsible for the reactiva-
tion of chronic infection in vivo remain poorly understood [2,4].
Studies in murine models of chronic toxoplasmosis have
demonstrated that CD8 T cells are pivotal for long-term
protection [3]. Paradoxically, despite a robust CD8 T cell
response during the acute phase of infection, long-term immunity
against this pathogen is compromised in susceptible mouse strains,
leading to reactivation and host mortality. Differential suscepti-
bility to T. gondii reactivation in AIDS patients was also noted in a
study conducted during the pre-HAART era, which reported that
only 30% of AIDS patients with low CD4 T cell count and
Toxoplasma seropositivity, who were not on effective prophylaxis,
developed reactivated toxoplasmosis [5]. Why does a modest
subset of this high-risk group develop TE? Considering that
memory CD8 T cells can persist for a lifetime and can mediate
protective recall responses upon antigen reencounter in other
infectious diseases [6], it remains to be addressed whether this
differential outcome is a consequence of potential attrition of T.
gondii–specific memory CD8 T cells due to genetic polymorphisms
or other microenvironment-associated factors. Recent studies from
our group, which utilized a susceptible mouse model (C57BL/6),
have demonstrated that CD8 T cells during the later phase of
chronic toxoplasmosis exhibit progressive attrition of functionality,
increased apoptosis, and poor recall response along with elevated
expression of PD-1, an inhibitory receptor-a phenomenon referred
to as CD8 exhaustion [7]. Concomitant with graded CD8
exhaustion, parasites undergo reactivation resulting in the
mortality of the infected host (Figure 1). While the paradigm of
CD8 exhaustion has been extensively explored in chronic viral
models, it is just beginning to unfold in parasitic infections. Unlike
chronic viral models of CD8 exhaustion, which are characterized
by persistent high viremia, the T. gondii model represents a unique
situation where, despite initial control of parasitemia, CD8 T cells
eventually become exhausted [7,8]. Considering that current
drugs against T. gondii are toxic and inefficacious against the
encysted bradyzoite stage of the parasite [2,3], a thorough
understanding of T cell exhaustion during chronic toxoplasmosis
is critical for the development of improved immunotherapeutics
against this pathogen. Significantly, our laboratory has demon-
strated that a blockade of PD-1 interaction with its receptor PD-
L1, via anti-PD-L1 antibody treatment of chronically infected
animals, not only reinvigorates CD8 response and controls
parasite reactivation but also prevents host mortality [7].
CD8 Polyfunctionality
Polyfunctionality, i.e. the capacity of a single T cell to display
multiple functions, is one of the hallmarks of robust CD8 response.
This is emphasized by the observation that virus-specific
polyfunctional CD8 T cell response, rather than absolute CD8
number, correlates with superior viral control in HIV-infected
nonprogressors [9]. Examination of the polyfunctional (IFNc,
Granzyme B, TNFa, and IL-2) CD8 subset in T. gondii–infected
animals revealed that concomitant with Toxoplasma reactivation
and elevated CD8-mediated PD-1 expression, the frequency of
polyfunctional CD8 T cells declined sharply both in spleen and
brain [7,10]. Since T-box factors T-bet and Eomesodermin play
an important role in mediating CD8 functionality [11], investiga-
tion of the transcriptional profile revealed a decrease in both T-bet
and Eomes expression in CD8 T cells. Significantly, treatment of
chronically infected mice with aPD-L1 not only rescued bi-
functional and tri-functional CD8 response but also augmented T-
bet and Eomes expression [7,10]. Although aPD-L1 therapy
revived CD8 polyfunctionality, IL-2 expression remained refrac-
tory to this treatment [10]. Apart from the per-cell decrease of
functionality, preferential apoptosis of polyfunctional CD8 T cells
could also account for the attrition of polyfunctional response
during chronic toxoplasmosis. In agreement with this notion,
polyfunctional memory CD8 T cells preferentially expressed high
PD-1 levels which rendered them susceptible to apoptosis [12].
Combined, this suggests that an altered transcriptional profile and
preferential apoptosis result in attrition of polyfunctional CD8
Citation: Bhadra R, Khan IA (2012) Redefining Chronic Toxoplasmosis—A T Cell
Exhaustion Perspective. PLoS Pathog 8(10): e1002903. doi:10.1371/journal.ppat.
1002903
Editor: Laura J. Knoll, University of Wisconsin Medical School, United States of
America
Published October 11, 2012
Copyright:  2012 Bhadra, Khan. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: Funding was provided by NIH grant AI-33325 to IAK. The funders had
no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests
exist.
* E-mail: imti56@gwu.edu
PLOS Pathogens | www.plospathogens.org 1 October 2012 | Volume 8 | Issue 10 | e1002903
Figure 1. CD8 exhaustion during chronic toxoplasmosis. During the later phases of chronic toxoplasmosis, concomitant with elevated
mortality, encysted bradyzoites (parasites in green) undergo reactivation. This process involves T. gondii parasites undergoing stage conversion from
quiescent, slow-replicating bradyzoites to highly motile, fast-replicating tachyzoites (parasites shown in red). Parasite reactivation results in disease
recrudescence and eventual host mortality from toxoplasmic encephalitis. Cytokines such as IFNc and TNFa as well cytotoxicity play an important
role in controlling T. gondii infection. During chronic toxoplasmosis, CD8 T cells progressively fail to produce optimal IFNc or TNFa and mediate
cytotoxicity. Additionally, their ability to simultaneously exhibit all these functions (polyfunctionality) is lost. This is significant considering that
improved pathogen control in HIV+ nonprogressors has been shown to be strongly correlated with CD8 polyfunctionality. This loss of CD8
polyfunctionality is concomitant with elevated PD-1 expression on CD8 T cells, decreased expression of transcription factors T-bet and Eomes, and
elevated CD8 apoptosis. It is likely that an altered transcriptional profile in combination with PD-1–mediated apoptosis results in loss of
polyfunctional CD8 T cells over time. This phenomenon involving graded attrition of CD8 functionality is referred to as CD8 exhaustion.
doi:10.1371/journal.ppat.1002903.g001
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response during chronic toxoplasmosis. Considering that T cell
fate imprinting can occur as early as the first cell division [13], that
raises the following question: Are CD8 T cells programmed to
become dysfunctional at the very beginning? Preliminary studies
using drug treatment demonstrate that early rather the than late
intervention is critical for maintaining optimal CD8 polyfunction-
ality and preventing high PD-1 expression [7]. This suggests that
high antigen burden or inflammation (including anti-inflammatory
factors) or both during the acute phase of infection may be
responsible for development of CD8 exhaustion during the late
chronic stage of infection.
Skewed Memory CD8 Development
Memory CD8 T cells are critical for long-term protection
against intracellular pathogens [14]. During chronic toxoplasmo-
sis, the majority of T. gondii–specific polyfunctional CD8 T cells
exhibit cardinal markers of memory phenotype CD44 and CD127
[12]. Yet in contrast to acute infection models, these memory CD8
T cells exhibit high PD-1 expression [12]. Robust recall response
upon secondary challenge is one of the hallmarks of potent CD8
memory development [15]. However, CD8 T cells during the later
phases of chronic response are deficient in this regard [7]. Further,
subset-specific analysis demonstrated that PD-1–expressing mem-
ory phenotype CD8 T cells expressed high levels of CD43, a
marker of effector CD8 lineage [12]. Incidentally, CD43hi CD8 T
cells have been shown to elicit a poor recall response in a Sendai
virus model [16]. Despite the expression of effector lineage–
associated marker CD43, PD-1hi CD8 T cells expressed relatively
high levels of anti-apoptotic molecule Bcl-2, a hallmark of
conventional memory CD8 T cells [12,17]. Taken together this
suggests that while PD-1hi CD8 T cells display both memory and
effector lineage characteristics, they represent a phenotype distinct
from conventional memory and effector CD8 T cells generated in
nonchronic models of infection. Considering that IL-7 and IL-15
are critical for homeostasis of memory CD8 T cells, it will be
important to determine if this skewed phenotype results in poor
responsiveness to these cytokines and whether immunotherapy
with these cytokines is able to rescue or prevent CD8 exhaustion
[3,18].
Role of Positive Costimulatory Signals during the
Rescue
A recent study from our laboratory demonstrated that a block-
ade of negative signals such as PD-1-PD-L1 alone is insufficient for
the rescue of exhausted CD8 T cells, and positive costimulatory
signals, namely the CD40-CD40L pathway, play a pivotal role
during this process [10]. Using a mixed bone marrow chimera
(Wild-type:CD402/2) approach, our group demonstrated that
CD40 expression directly on CD8 T cells has a minimal impact
on their functionality or development or PD-1 expression [10].
However, CD40 sufficiency on CD8 T cells plays a critical role
during aPD-L1–mediated rescue of CD8 response in terms of
optimal expansion and polyfunctional CD8 response develop-
ment. Significantly, CD8-extrinsic CD40 signaling is also a
major contributor to the process. In absence of CD40-CD40L
signaling, CD40-deficient CD4 T cells in aPD-L1–treated
chimeras do not develop a robust T follicular helper (Tfh) cell
response or express copious IL-21 [10]. Incidentally, the role of
IL-21 in preventing CD8 exhaustion is well established in
chronic viral models [8]. It is likely that both CD40L-expressing
antigen presenting cells (APC) and CD4 T cells interact with
CD40+ CD8 T cells to mediate CD8 rescue in aPD-L1–treated
mice. In future studies, it will be important to decipher the
differential contribution of Tfh and APCs to the rescue of
exhausted CD8 T cells.
Future Perspectives
Current studies on CD8 exhaustion provide a new insight into
chronic toxoplasmosis and bear the promise for improved
immunotherapeutics against this pathogen. However several issues
remain unaddressed. Although aPD-L1 treatment prevented the
mortality of chronically infected animals, this was only achieved
with prolonged antibody therapy. Extended aPD-L1 treatment
carries the risk of developing autoimmune reactions. Additionally,
aPD-L1 treatment was only efficacious on PD-1int CD8 T cells,
and PD-1hi CD8 T cells remained refractory to its anti-apoptotic
effects [7]. This potentially raises the question of whether PD-1hi
cells coexpress other inhibitory receptors (Tim3, Lag3, 2B4, etc.),
which renders them insensitive to aPD-L1 therapy [19]. Another
issue that needs to be addressed: Are strains such as Balb/C
resistant to Toxoplasma because they do not develop exhaustion? If
so, a microarray analysis of T. gondii–specific CD8 T cells from
resistant and susceptible mice stains will be important in
unraveling novel pathways and molecules that may be involved
in this divergent outcome to Toxoplasma challenge. Using such an
approach will permit us to develop better immunotherapy not only
against Toxoplasma but also other chronic infectious diseases and
cancers.
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